L
Louis Ferreira
Guest
Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients TOKYO, September 23, 2020 — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” (generic name: favipiravir, “Avigan”) conducted […]
The post Avigan Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 appeared first on Fuji Addict.
Related posts:
Continue reading...
The post Avigan Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 appeared first on Fuji Addict.
Related posts:
- Unpacking the Stimulus Bill for Freelancers by Fujifilm Call NOW! Updated
- Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies As Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
- Significant Expansion of Production Facilities For Biopharmaceuticals in Denmark
Continue reading...